Characteristics of 501 patients with SLE and polyautoimmunity
| Variable | polyautoimmunity, (n=501) |
|---|---|
| Epidemiological characteristics | |
| Sex (female), n (%) | 473 (94.4) |
| Ethnicity, caucasian (%) | 456 (93.6) |
| Age at disease diagnosis, mean (SD) | |
| Age>50 years, n (%) | 134 (15.4) |
| Smoke | |
| Non-smoker, n (%) | 274 (59.4) |
| Ex-smoker, n (%) | 120 (26.0) |
| Smoker, n (%) | 67 (14.5) |
| Oral contraceptive | |
| Non-oral contraceptive, n (%) | 258 (69.0) |
| Exoral contraceptive, n (%) | 107 (28.6) |
| Oral contraceptive, n (%) | 9 (2.4) |
| Family history , n (%) | 60 (15.7) |
| Clinical characteristic | |
| Disease duration (months), median(p75-p25) | 212.0 (120.8–289.0) |
| Malar rash, n (%) | 253 (50.8) |
| Discoid rash, n (%) | 94 (19.1) |
| Photosensitivity, n (%) | 293 (59.7) |
| Oral ulcers, n (%) | 218 (44.4) |
| Arthritis, n (%) | 393 (79.4) |
| Pleuritis, n (%) | 105 (21.3) |
| Pericarditis, n (%) | 86 (17.3) |
| Renal disorder, n (%) | 132 (26.6) |
| Neurological disorder, n (%) | 45 (9.1) |
| hemolytic anemia, n (%) | 49 (9.9) |
| leukopenia, n (%) | 293 (59.3) |
| thrombocytopenia, n (%) | 106 (21.8) |
| Sjögren’s syndrome, n (%) | 127 (25.7) |
| Antiphospholipid syndrome, n (%) | 74 (14.9) |
| mixed connective tissue disease, n (%) | 14 (2.7) |
| Raynaud’s phenomenon, n(%) | 226 (45.8) |
| Lupus Nephritis, n (%) | 131 (26.5) |
| Pulmonary fibrosis, n (%) | 25 (5.0) |
| Pulmonary hypertension, n (%) | 17 (3.4) |
| Laboratory characteristic | |
| ANA+, n (%) | 497 (99.0) |
| Anti-DNA+, n (%) | 350 (71.0) |
| Anti-sm +, n (%) | 110 (22.8) |
| Anti-RNP, n (%) | 164 (34.1) |
| Anti-ro, n (%) | 193 (39.9) |
| Anti-la, n (%) | 104 (21.4) |
| AL+, n (%) | 70 (20.3) |
| Therapeutic regimen | |
| Glucocorticoids, n (%) | 439 (91.1) |
| Methotrexate, n (%) | 120 (24.7) |
| Hydroxychloroquine, n (%) | 369 (76.7) |
| Azathioprine, n (%) | 173 (36.0) |
| Cyclophosphamide, n (%) | 95 (19.7) |
| Mycophenolate mofetilo, n (%) | 60 (12.4) |
| Rituximab, n (%) | 44 (9.1) |
| Inmunoglobulin, n (%) | 23 (4.8) |